Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 10.
doi: 10.1111/ajco.14185. Online ahead of print.

Multidisciplinary Implementation of Neoadjuvant Therapy for Early Breast Cancer in a Middle-income Country-Real-world Challenges in Malaysia

Nur Aishah Mohd Taib  1   2 , Nur Fadhlina Abdul Satar  3 , Adibah Ali  4 , Chun Sen Lim  5 , Rohaizak Muhammad  6 , Navarasi S Raja Gopal  7 , Yueh Ni Lim  8 , Shantini Arasaratnam  9 , Juliana Abdul Latiff  10 , Anita Baghawi  11 , Char Hong Ng  12 , Mastura Md Yusof  13   14
Affiliations

Multidisciplinary Implementation of Neoadjuvant Therapy for Early Breast Cancer in a Middle-income Country-Real-world Challenges in Malaysia

Nur Aishah Mohd Taib et al. Asia Pac J Clin Oncol. .

Abstract

Aim: Neoadjuvant therapy (NAT) is not widely employed for the management of patients with early breast cancer (EBC) in Malaysia. We sought to identify barriers to NAT and explore solutions for improving equitable, safe, and timely access to NAT in these patients.

Methods: We used deliberative stakeholder consultation, a descriptive qualitative study design, for data collection. Sixteen breast cancer specialists (seven breast surgeons, seven clinical oncologists, one radiologist, and one pathologist) from 11 tertiary centers in Malaysia were purposively recruited. Deliberations were recorded, transcribed, and thematically analyzed to generate analytical and deliberative outputs. A literature search was performed to ensure that consensus statements were aligned with scientific evidence and clinical practice guidelines.

Results: Four barrier themes affecting NAT implementation were derived: (1) diagnostic delays, (2) lack of access to oncology services, (3) patient low acceptance of NAT, and (4) high treatment costs. We highlighted potential solutions to address each barrier. Seven key areas for improvement were identified across the EBC care pathway: (1) rational use of imaging modalities, (2) biopsy sampling technique, (3) standardized histopathological reporting, (4) patient selection for NAT, (5) marker clip insertion, (6) monitoring during NAT, and (7) surgical axillary management. Expert recommendations for practice-change interventions were in alignment with published international, national, and institutional guidelines.

Conclusion: Barriers to NAT in Malaysia are multifactorial. This study draws on a multidisciplinary stakeholder perspective to define real-world challenges faced by breast cancer specialists and provides recommendations for implementing guideline-recommended practices for NAT utilization in the local healthcare setting.

Keywords: barriers | early breast cancer | implementation | multidisciplinary | neoadjuvant therapy.

PubMed Disclaimer

References

    1. M. Kaufmann, G. V. von Minckwitz, R. Smith, et al., “International Expert Panel on the Use of Primary (preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendation,” Journal of Clinical Oncology 21 (2003): 2600–2608.
    1. L. A. Korde, M. R. Somerfield, L. A. Carey, et al., “Neoadjuvant Chemotherapy, Endocrine Therapy and Targeted Therapy for Breast Cancer: ASCO Guideline,” Journal of Clinical Oncology 39 (2020): 1485–1505.
    1. F. Cardoso, S. Kyriakides, S. Ohno, et al., “Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐up,” Annals of Oncology 30 (2019): 1194–1220.
    1. H. J. Burstein, G. Curigliano, S. Loibl, et al., “Estimating the Benefits of Therapy for Early‐stage Breast Cancer: The St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019,” Annals of Oncology 30 (2019): 1541–1557.
    1. D. Mauri, N. Pavlidis, and J. P. Ioannidis, “Neoadjuvant versus Adjuvant Systemic Treatment in Breast Cancer: A Meta‐analysis,” JNCI: Journal of the National Cancer Institute 97 (2005): 188–194.

Grants and funding

LinkOut - more resources